QOP
ALT icon

Quinn Opportunity Partners’s Altimmune ALT Stock Holding History

Quinn Opportunity Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-105,000
Closed -$1.18M – 256
2023
Q4 		$1.18M Buy
+105,000
New +$438K 0.12% 114

Other funds holding ALT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Quinn Opportunity Partners's ALT Position: Q1 2024 in Review

Quinn Opportunity Partners sold out of Altimmune (ALT) in Q1 2024, closing a stake of 105,000 shares — an estimated $1.18M sold.

Quinn Opportunity Partners first reported a position in ALT in Q4 2023 and held it in 1 quarter. The position peaked at $1.18M in Q4 2023. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • Quinn Opportunity Partners reported no remaining Altimmune position as of Q1 2024 after selling out during the quarter.
  • Quinn Opportunity Partners sold 105,000 Altimmune shares in Q1 2024, an estimated $1.18M.
  • Quinn Opportunity Partners first reported a position in Altimmune in Q4 2023 and held it in 1 quarter.
  • Quinn Opportunity Partners's Altimmune position peaked at $1.18M in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Quinn Opportunity Partners's 13F filing for Q1 2024, filed 15 May 2024.